591
Views
2
CrossRef citations to date
0
Altmetric
Review Articles

Bacteriophages: the dawn of a new era in periodontal microbiology?

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 212-223 | Received 31 Oct 2022, Accepted 15 Feb 2023, Published online: 08 Mar 2023

References

  • Ackermann HW. 1998. Tailed bacteriophages: the order caudovirales. Adv Virus Res. 51:135–201.
  • Alanis AJ. 2005. Resistance to antibiotics: are we in the post-antibiotic era? Arch Med Res. 36:697–705.
  • Alves DR, Perez-Esteban P, Kot W, Bean JE, Arnot T, Hansen LH, Enright MC, Jenkins ATA. 2016. A novel bacteriophage cocktail reduces and disperses Pseudomonas aeruginosa biofilms under static and flow conditions. Microb Biotechnol. 9:61–74.
  • Ando H, Lemire S, Pires DP, Lu TK. 2015. Engineering Modular Viral Scaffolds for Targeted Bacterial Population Editing. Cell Syst. 1:187–196.
  • Barr JJ, Auro R, Furlan M, Whiteson KL, Erb ML, Pogliano J, Stotland A, Wolkowicz R, Cutting AS, Doran KS, Salamon P. 2013. Bacteriophage adhering to mucus provide a non-host-derived immunity. Proc Natl Acad Sci. 110(26):10771–10776.
  • Ben-Zaken H, Kraitman R, Coppenhagen-Glazer S, Khalifa L, Alkalay-Oren S, Gelman D, Ben-Gal G, Beyth N, Hazan R. 2021. Isolation and characterization of Streptococcus mutans phage as a possible treatment agent for caries. Viruses. 13(5):825.
  • Bergh Ø, Børsheim KY, Bratbak G, Heldal M. 1989. High abundance of viruses found in aquatic environments. Nature. 340(6233):467–468.
  • Betley MJ, Mekalanos JJ. 1985. Staphylococcal enterotoxin A is encoded by phage. Science. 229(4709):185–187.
  • Borysowski J, Górski A. 2008. Is phage therapy acceptable in the immunocompromised host? Int J Infect Dis. 12:466–471.
  • Bourdin G, Navarro A, Sarker SA, Pittet AC, Qadri F, Sultana S, Cravioto A, Talukder KA, Reuteler G, Brüssow H. 2014. Coverage of diarrhoea-associated Escherichia coli isolates from different origins with two types of phage cocktails. Microb Biotechnol. 7:165–176.
  • Brüssow H, Canchaya C, Hardt W-D. 2004. Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion. Microbiol Mol Biol Rev. 68(3):560–602, table of contents.
  • Castillo-Ruiz M, Vinés ED, Montt C, Fernández J, Delgado JM, Hormazábal JC, Bittner M. 2011. Isolation of a Novel Aggregatibacter actinomycetemcomitans Serotype b Bacteriophage Capable of Lysing Bacteria within a Biofilm. Appl Environ Microbiol. 77:3157.
  • Chan BK, Abedon ST, Loc-Carrillo C. 2013. Phage cocktails and the future of phage therapy. Future Microbiol. 8:769–783.
  • Chan BK, Turner PE, Kim S, Mojibian HR, Elefteriades JA, Narayan D. 2018. Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol Med Public Health. 2018:60.
  • Chibani-Chennoufi S, Sidoti J, Bruttin A, Kutter E, Sarker S, Brüssow H. 2004. In vitro and In vivo Bacteriolytic activities of Escherichia coli Phages: implications for phage therapy. Antimicrob Agents Chemother. 48(7):2558–2569.
  • Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. Science. 284:1318–1322.
  • Dalmasso M, De Haas E, Neve H, Strain R, Cousin FJ, Stockdale SR, Ross RP, Hill C. 2015. Isolation of a Novel Phage with activity against Streptococcus mutans Biofilms. PLoS One. 10(9):e0138651.
  • Dams D, Brøndsted L, Drulis-Kawa Z, Briers Y. 2019. Engineering of receptor-binding proteins in bacteriophages and phage tail-like bacteriocins. Biochem Soc Trans. 47:449–460.
  • Dunsing V, Irmscher T, Barbirz S, Chiantia S. 2019. Purely polysaccharide-based biofilm Matrix provides size-selective diffusion barriers for nanoparticles and bacteriophages. Biomacromolecules. 10:3842–3854.
  • Fenton M, Ross P, Mcauliffe O, O’Mahony J, Coffey A. 2010. Recombinant bacteriophage lysins as antibacterials. Bioeng Bugs. 1:9.
  • Fischetti VA. 2008. Bacteriophage lysins as effective Antibacterials. Curr Opin Microbiol. 11:393.
  • Flemming HC, Wingender J. 2010. The biofilm matrix. Nat Rev Microbiol. 8(9):623–633.
  • Fraser JS, Yu Z, Maxwell KL, Davidson AR. 2006. Ig-like domains on bacteriophages: a tale of promiscuity and deceit. J Mol Biol. 359(2):496–507.
  • Gordillo Altamirano FL, Barr JJ. 2019. Phage therapy in the Postantibiotic Era. Clin Microbiol Rev. 32(2):e00066-18.
  • Goshorn SC, Schlievert PM. 1989. Bacteriophage association of streptococcal pyrogenic exotoxin type C. J Bacteriol. 171(6):3068–3073.
  • Hajishengallis G, Darveau RP, Curtis MA. 2012. The keystone-pathogen hypothesis. Nat Rev Microbiol. 10:717–725.
  • Hajishengallis G, Lamont RJ. 2012. Beyond the red complex and into more complexity: the polymicrobial synergy and dysbiosis (PSD) model of periodontal disease etiology. Mol Oral Microbiol. 27:409–419.
  • Hampton HG, Watson BNJ, Fineran PC. 2020. The arms race between bacteria and their phage foes. Nature. 577(7790):327–336.
  • Hendrix RW, Smith MCM, Burns RN, Ford ME, Hatfull GF. 1999. Evolutionary relationships among diverse bacteriophages and prophages: all the world’s a phage. Proc Natl Acad Sci USA. 96:2192–2197.
  • Henriksen K, Rørbo N, Rybtke ML, Martinet MG, Tolker-Nielsen T, Høiby N, Middelboe M, Ciofu O. 2019. P aeruginosa flow-cell biofilms are enhanced by repeated phage treatments but can be eradicated by phage-ciprofloxacin combination. Pathog Dis. 77(2):ftz011.
  • Holmes RK. 2000. Biology and molecular epidemiology of diphtheria toxin and the tox gene. J Infect Dis. 181(Suppl 1):S156–S167.
  • Hosseinidoust Z, Tufenkji N, van de Ven TGM. 2013. Formation of biofilms under phage predation: considerations concerning a biofilm increase. Biofouling. 29:457–468.
  • Høyland-Kroghsbo NM, Mærkedahl RB, Svenningsen S l 2013. A quorum-sensing-induced bacteriophage defense mechanism. mBio. 4:e00362-12.
  • Huang A, Friesen J, Brunton JL. 1987. Characterization of a bacteriophage that carries the genes for production of Shiga-like toxin 1 in Escherichia coli. J Bacteriol. 169(9):4308–4312.
  • Jennes S, Merabishvili M, Soentjens P, et alPang KW, Rose T, Keersebilck E, Soete O, François PM, Teodorescu S, Verween G, Verbeken G. 2017. Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury-a case report. Crit Care. 21:1–3.
  • Kabwe M, Brown TL, Dashper S, Speirs L, Ku H, Petrovski S, Chan HT, Lock P, Tucci J. 2019. Genomic, morphological and functional characterisation of novel bacteriophage FNU1 capable of disrupting Fusobacterium nucleatum biofilms. Scientific Reports. 9(1):1–12.
  • Kang K, Imamovic L, Misiakou MA, Bornakke Sørensen M, Heshiki Y, Ni Y, Zheng T, Li J, Ellabaan MM, Colomer-Lluch M, Rode AA. 2021. Expansion and persistence of antibiotic-specific resistance genes following antibiotic treatment. Gut Microbes. 13(1):1900995.
  • Karaolis DKR, Somara S, Maneval DR, Johnson JA, Kaper JB. 1999. A bacteriophage encoding a pathogenicity island, a type-IV pilus and a phage receptor in cholera bacteria. Nature. 399:6734–6379.
  • Khalifa L, Brosh Y, Gelman D, Coppenhagen-Glazer S, Beyth S, Poradosu-Cohen R, Que YA, Beyth N, Hazan R. 2015. Targeting Enterococcus faecalis biofilms with phage therapy. Appl Environ Microbiol. 81(8):2696–2705.
  • Kifelew LG, Warner MS, Morales S, Thomas N, Gordon DL, Mitchell JG, Speck PG. 2020. Efficacy of lytic phage cocktails on staphylococcus aureus and pseudomonas aeruginosa in mixed-species planktonic cultures and biofilms. Viruses. 12(5):559.
  • Knecht LE, Veljkovic M, Fieseler L. 2020. Diversity and Function of Phage Encoded Depolymerases. Front Microbiol. 10:2949.
  • Koskella B, Brockhurst MA. 2014. Bacteria-phage coevolution as a driver of ecological and evolutionary processes in microbial communities. FEMS Microbiol Rev. 38:916–931.
  • Lin DM, Koskella B, Lin HC. 2017. Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther. 8:162.
  • Liu S, Lu H, Zhang S, Shi Y, Chen Q. 2022. Phages against Pathogenic Bacterial Biofilms and Biofilm-Based Infections: a review. Pharmaceutics. 14:427.
  • Lu TK, Collins JJ. 2007. Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci USA. 104(27):11197–11202.
  • Ly M, Abeles SR, Boehm TK, Robles-Sikisaka R, Naidu M, Santiago-Rodriguez T, Pride DT. 2014. Altered oral viral ecology in association with periodontal disease. mBio. 5(3):e01133-14.
  • Machuca P, Daille L, Vinés E, Berrocal L, Bittner M. 2010. Isolation of a Novel Bacteriophage Specific for the Periodontal Pathogen Fusobacterium nucleatum. Appl Environ Microbiol. 76(21):7243–7250.
  • Macià MD, Rojo-Molinero E, Oliver A. 2014. Antimicrobial susceptibility testing in biofilm-growing bacteria. Clinical Microbiology and Infection. 20:981–990.
  • Malik S, Nehra K, Rana JS. 2021. Bacteriophage cocktail and phage antibiotic synergism as promising alternatives to conventional antibiotics for the control of multi-drug-resistant uropathogenic Escherichia coli. Virus Res. 302:198496.
  • Martínez A, Kuraji R, Kapila YL. 2021. The human oral virome: shedding light on the dark matter. Periodontol. 87:282–298.
  • Maurelli AT, Fernández RE, Bloch CA, Rode CK, Fasano A. 1998. Black holes” and bacterial pathogenicity: a large genomic deletion that enhances the virulence of Shigella spp. and enteroinvasive Escherichia coli. Proc Natl Acad Sci USA. 95(7):3943–3948.
  • Miller MB, Bassler BL. 2001. Quorum sensing in bacteria. Annu Rev Microbiol. 55:165–199.
  • Mitchell HL, Dashper SG, Catmull D v, Paolini RA, Cleal SM, Slakeski N, Tan KH, Reynolds EC. 2010. Treponema denticola biofilm-induced expression of a bacteriophage, toxin-antitoxin systems and transposases. Microbiology. 156(Pt 3):774–788.
  • Modi SR, Lee HH, Spina CS, Collins JJ. 2013. Antibiotic treatment expands the resistance reservoir and ecological network of the phage metagenome. Nature. 499(7457):219–222.
  • Mushegian AR. 2020. Are there 10 31 Virus particles on earth, or more, or fewer? J Bacteriol. 202(9):e00052-20.
  • O’Flaherty S, Ross RP, Coffey A. 2009. Bacteriophage and their lysins for elimination of infectious bacteria. FEMS Microbiol Rev. 33:801–819.
  • Ojha A, Anand M, Bhatt A, Kremer L, Jacobs WR, Hatfull GF. 2005. GroEL1: a dedicated chaperone involved in mycolic acid biosynthesis during biofilm formation in mycobacteria. Cell. 123:861–873.
  • Oliveira H, Boas DV, Mesnage S, Kluskens LD, Lavigne R, Sillankorva S, Secundo F, Azeredo J. 2016. Structural and enzymatic characterization of ABgp46, a novel phage endolysin with broad anti-gram-negative bacterial activity. Front Microbiol. 7:208.
  • Pei R, Lamas-Samanamud GR. 2014. Inhibition of biofilm formation by T7 bacteriophages producing quorum-quenching enzymes. Appl Environ Microbiol. 80(17):5340–5348.
  • Pires DP, Melo LDR, Azeredo J. 2021. Understanding the complex phage-host interactions in biofilm communities. Annu Rev Virol. 8:73–94.
  • Pires DP, Melo LDR, Vilas Boas D, Sillankorva S, Azeredo J. 2017. Phage therapy as an alternative or complementary strategy to prevent and control biofilm-related infections. Curr Opin Microbiol. 39:48–56.
  • Pires DP, Oliveira H, Melo LDR, Sillankorva S, Azeredo J. 2016. Bacteriophage-encoded depolymerases: their diversity and biotechnological applications. Appl Microbiol Biotechnol. 100(5):2141–2151.
  • Pride DT, Salzman J, Haynes M, Rohwer F, Davis-Long C, White RA, Loomer P, Armitage GC, Relman DA. 2012. Evidence of a robust resident bacteriophage population revealed through analysis of the human salivary virome. Isme J. 6:915–926.
  • Publications service. 2007. On an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr. F. D’Herelle, presented by Mr. Roux. 1917. Res Microbiol. 158:553–554.
  • Qin X, Sun Q, Yang B, Pan X, He Y, Yang H. 2017. Quorum sensing influences phage infection efficiency via affecting cell population and physiological state. J Basic Microbiol. 57:162–170.
  • Rajabi Z, Kermanshahi R, Dallal MMS, Erfani Y, Ranjbar R. 2021. Isolation of the Bacteriophages Inhibiting the Expression of the Genes Involved in Biofilm Formation by Streptococcus mutans. Jundishapur J Microbiol. 14:1.
  • Regeimbal JM, Jacobs AC, Corey BW, Henry MS, Thompson MG, Pavlicek RL, Quinones J, Hannah RM, Ghebremedhin M, Crane NJ, Zurawski DV. 2016. Personalized Therapeutic Cocktail of Wild Environmental Phages Rescues Mice from Acinetobacter baumannii Wound Infections. Antimicrob Agents Chemother. 60(10):5806–16.
  • Sakuragi Y, Kolter R. 2007. Quorum-sensing regulation of the biofilm matrix genes (pel) of Pseudomonas aeruginosa. J Bacteriol. 189(14):5383–5386.
  • Salmond GPC, Fineran PC. 2015. A century of the phage: past, present and future. Nat Rev Microbiol. 13(12):777–786.
  • Sandmeier H, Bar K, Meyer J. 1993. Search for bacteriophages of black-pigmented Gram-negative anaerobes from dental plaque. FEMS Immunol Med Microbiol. 6:193–194.
  • Schlafer S, Meyer RL, Dige I, Regina VR. 2017. Extracellular DNA Contributes to Dental Biofilm Stability. Caries Res. 51:436–442.
  • Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, Barr JJ, Reed SL, Rohwer F, Benler S, Segall AM. 2017. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother. 61(10):e00954-17.
  • Sekulovic O, Meessen-Pinard M, Fortier LC. 2011. Prophage-stimulated toxin production in Clostridium difficile NAP1/027 lysogens. J Bacteriol. 193(11):2726–2734.
  • Steier L, De Oliveira SD, De Figueiredo JAP. 2019. Bacteriophages in Dentistry—State of the Art and Perspectives. Dent J. 7:6.
  • Stern A, Sorek R. 2011. The phage-host arms race: shaping the evolution of microbes. Bioessays. 33:43–51.
  • Stevens RH, Hammond BF, Lai CH. 1982. Characterization of an inducible bacteriophage from a leukotoxic strain of Actinobacillus actinomycetemcomitans. Infect Immun. 35(1):343–349.
  • Stevens RH, Moura Martins Lobo dos Santos C d, Zuanazzi D, Accioly Mattos M d, Ferreira DF, Kachlany SC, Tinoco EMB. 2013. Prophage induction in lysogenic Aggregatibacter actinomycetemcomitans cells co-cultured with human gingival fibroblasts, and its effect on leukotoxin release. Microb Pathog. 54:54–59.
  • Szafrański SP, Slots J, Stiesch M. 2021. The human oral phageome. Periodontol 2000. 86(1):79–96.
  • Szafrański SP, Winkel A, Stiesch M. 2017. The use of bacteriophages to biocontrol oral biofilms. J Biotechnol. 250:29–44.
  • Tan D, Dahl A, Middelboe M. 2015. Vibriophages differentially influence biofilm formation by Vibrio anguillarum Strains. Appl Environ Microbiol. 81(13):4489–4497.
  • Tetz G, Tetz V. 2016. Bacteriophage infections of microbiota can lead to leaky gut in an experimental rodent model. Gut Pathog. 8:1–4.
  • Tian F, Li J, Nazir A, Tong Y. 2021. Bacteriophage – a promising alternative measure for bacterial biofilm control. undefined. 14:205–217.
  • Tinoco EMB, Stevens R, Haubek D, Lai CH, Balachandran S, Preus H. 1997. Relationship of serotype, leukotoxin gene type and lysogeny in Actinobacillus actinomycetemcomitans to periodontal disease status. Eur J Oral Sci. 105:310–317.
  • Tinoco JM, Liss N, Zhang H, Nissan R, Gordon W, Tinoco E, Sassone L, Stevens R. 2017. Antibacterial effect of genetically-engineered bacteriophage ϕEf11/ϕFL1C(Δ36)P nisA on dentin infected with antibiotic-resistant Enterococcus faecalis. Arch Oral Biol. 82:166–170.
  • van der Kamp I, Draper LA, Smith MK, Buttimer C, Ross RP, Hill C. 2020. A new phage lysin isolated from the oral microbiome targeting Streptococcus pneumoniae. Pharmaceuticals. 13:1–19.
  • Willi K, Sandmeier H, Kulik EM, Meyer J. 1997. Transduction of antibiotic resistance markers among Actinobacillus actinomycetemcomitans strains by temperate bacteriophages Aa phi 23. Cell Mol Life Sci. 53(11–12):904–910.
  • Wright GD. 2007. The antibiotic resistome: the nexus of chemical and genetic diversity. Nat Rev Microbiol. 5(3):175–186.
  • Yap ML, Rossmann MG. 2014. Structure and function of bacteriophage T4. Future Microbiol. 9(12):1319–1327.
  • Yeung MK, Kozelsky CS. 1997. Transfection of actinomyces spp. by Genomic DNA of bacteriophages from human dental plaque. Plasmid. 37(2):141–153.
  • Zelasko S, Gorski A, Dabrowska K. 2017. Delivering phage therapy per os: benefits and barriers. Expert Rev anti Infect Ther. 15(2):167–179.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.